PROJECTS

Logo.JPG

The MDR project (HIV multidrug resistance pathways in the EuResist Integrated DataBase) aims at estimating the prevalence and trend over time of MDR (multidrug resistance) in HIV patients, using descriptive statistics, retaining high value because of the large sample size and wide representativeness of the EIDB.

 

In addition, the project aims at identifying factors associated with development of MDR and deriving successful treatment strategies in MDR patients, based on GSS of possible rescue therapies: these challenging and ambitious tasks will benefit from machine learning approaches and the use of probabilistic models, under the responsibility of a multidisciplinary team with excellent specific and cross-talk capability, well-established through decennial cooperation within the EuResist consortium. 

The MDR project started at March 2019. The study group includes clinicians, virologists and modelers with specific strong expertise in HIV drug resistance: Dr. A. Sönnerborg (KI), Dr. M. Zazzi (UNISI), Dr. R. Kaiser (UNIKOELN), : Dr. A.M. Vandamme (Rega Institute)

NEW!

The Poster "Analysis of mutational history of multi-drug resistance with a mutagenetic tree model" will be presented at the next European Meeting on HIV & Hepatitis 2022 in Paris.

ViiV.png

Project supported by a grant from ViiV Healthcare S.r.l.

The Poster "Declining incidence of HIV multidrug resistance in Europe" has won the Best Poster Award at the 18th European AIDS Conference held Online & London, United Kingdom on October 27–30, 2021.

MDRaward.jpg

Publications

Analysis of mutational history of multi-drug resistance with a mutagenetic tree model, Martin Pirkl et al. 

European Meeting on HIV & Hepatitis 2022 (Paris)

Declining incidence of HIV multidrug resistance in Europe, J. Dewandre, J. Vercauteren, A.-M. Vandamme, B. Rossetti, M. Fabbiani, F. Incardona, A. Abecasis, C. Devaux, R. Kaiser, A. Sönnerborg, M. Zazzi, The EuResist Network study group

18th European AIDS Conference (EACS),  2021

 

4-Class Resistance is rare in treatment experienced patients across Europe

M. Zazzi, A.M. Vandamme, B. Rossetti, M. Fabbiani, F. Incardona, K. Theys, A. Abecasis, C. Devaux, R. Kaiser, A. Sönnerborg, G. Pasculli, J. Vercauteren for the EuResist Network study group

CROI 2020

Saladini F, Giannini A, Giammarino F, Maggiolo F, Vichi F, Corbelli GM, Galli A, Bigoloni A, Poli A, Santoro MM, Zazzi M, Castagna A. In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients. J Antimicrob Chemother. 2020 Sep 1;75(9):2547-2553. doi: 10.1093/jac/dkaa178. PMID: 32464638.

Saladini F, Giannini A, Boccuto A, Dragoni F, Appendino A, Albanesi E, Vicenti I, Zazzi M. Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations. Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01717-19. doi: 10.1128/AAC.01717-19. PMID: 31611362; PMCID: PMC7187585.

Saladini et al. paper immagine.jpg
CROI_2020-Poster-EuResist_V08_uploaded.j